secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001104659-23-026810
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva reports Q4 2022 royalties of $54.7M, pre-tax loss of $64.7M on $85.4M fair-value decline
--------------------------------------------------------------------------------

- Gross royalty revenues of $54.7M from GSK for RELVAR/BREO and ANORO ELLIPTA in Q4 2022.
- Income before taxes was a loss of $64.7M vs. income of $56.5M in Q4 2021, driven by $85.4M decline in fair value of investments.
- Net product sales of $14.6M from GIAPREZA and XERAVA in Q4 2022.
- Board authorized $100M share repurchase program; $30M convertible debt facility with Armata closed in January 2023.
- FDA granted priority review for SUL-DUR NDA; PDUFA date May 29, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923026810/0001104659-23-026810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923026810/tm238049d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer